Reframing RB Tumor Suppressor Dysfunction as a Therapeutic Vulnerability in Cancer.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• The retinoblastoma (RB) protein, a known tumor suppressor, has critical roles beyond cell-cycle regulation.
• RB inactivation is historically linked to tumorigenesis and resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i).
• Clinical data show inconsistent predictive value of RB status for CDK4/6i response.

Purpose of the Study:

• To re-evaluate the multifaceted roles of RB protein in cancer biology and therapeutic response.
• To explore how RB loss influences responses to chemotherapy and targeted therapies.
• To identify emerging strategies exploiting RB-deficient states in precision oncology.

Main Methods:

• Review of existing literature on RB protein biology.
• Analysis of clinical data regarding RB status and CDK4/6i response.
• Evaluation of RB's noncanonical functions in DNA repair, chromosomal stability, and transcriptional regulation.

Main Results:

• RB protein has broader noncanonical roles including DNA repair, apoptosis control, and transcriptional regulation.
• RB inactivation promotes replication stress, chromosomal instability, and transcriptional reprogramming.
• RB loss may create context-specific vulnerabilities exploitable by therapy.

Conclusions:

• RB's role in therapeutic response is complex and requires reconsideration beyond its function as a simple biomarker.
• Exploiting RB-deficient cellular vulnerabilities through monotherapy or combination approaches may expand precision oncology.
• Reframing RB dysfunction can inform novel treatment strategies for aggressive and treatment-resistant cancers.